Avadel Stock Rises After Acquisition Offer By Alkermes

2025-10-22 09:00:46

(MENAFN- AsiaNet News)

Alkermes will buy Avadel for up to $20 per share.
The consideration of $20 values Avadel at about $2.1 billion.
The deal is expected to close in the first quarter of 2026.

Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said that the companies have entered into a definitive agreement under which Alkermes will acquire Avadel for up to $20 per share.

The consideration of $20 values Avadel at about $2.1 billion and represents a premium of 12% from the stock's last closing price on Tuesday.

When Will The Deal Close?

The deal has been approved by the board of directors of both companies and is expected to close in the first quarter (Q1) of 2026. The deal is expected to be accretive upon closing, Alkermes said. The transaction includes Avadel's Lumryz for the treatment of cataplexy or excessive daytime sleepiness in patients over 7 years of age with narcolepsy.

AVDL stock is up 4% in the pre-market session.

Get updates to this developing story directly on Stocktwits.

MENAFN22102025007385015968ID1110232193

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.